Merck's 2nd Quarter: Highlights and Vulnerabilties | Market Check-Up, 8/12/13 | The Motley Fool

TL;DR

Merck's Q2 results were mixed, with earnings beating expectations but a decline in revenue. The company saw growth in its HPV vaccine and diabetes franchise, but is facing competition and patent expirations in the future.

Transcript

today we're diving deep on Dow component mk's second quarter results and taking a look at anything else investors may want to know about the big Pharma this is your Market checkup now Max MK had a bit of a mixed second quarter they beat on the bottom line earnings per share were were pretty good uh unfortunately the top line was not Revenue uh miss... Read More

Key Insights

• 👣 Gardasil, Merck's HPV vaccine, is experiencing impressive growth and is on track to be a blockbuster product.
• 😀 Merck's diabetes franchise is growing despite facing competition from other companies.
• 😘 China's market holds growth opportunities for Merck, but potential government intervention and lower drug pricing pose concerns.
• 😚 Patent expirations pose a significant challenge for Merck, with several drugs losing protection in the coming years.
• 🫁 Merck's imuno-oncology program and the outcome of its non-small cell lung cancer data are important catalysts to watch.
• ⚾ The success of Merck's base inhibitor for Alzheimer's disease would be significant for the company.
• ❓ Merck's future will be impacted by the performance of its Lamroliab drug in comparison to Bristol Myers Squibb's Nivolumab.

Questions & Answers

Q: What were the highlights and challenges of Merck's Q2 results?

Merck's HPV vaccine and diabetes franchise saw impressive growth, while revenue declined and the company faced competition and patent expirations.

Q: How is China's market affecting Merck's growth?

China is an important growth driver for Merck, but concerns arise from potential government intervention and lowered drug pricing.

Q: What were the factors contributing to Merck's declining revenue?

Patent expiration of Singulair and cancellation of distribution agreements in China affected Merck's revenue. However, management stated that sales would have been up 4% without these factors.

Q: Is it advisable for Merck to spin off its consumer health division and focus solely on pharmaceuticals?

While spinning off slower-growing divisions may benefit a company, Merck's management sees consumer health as a complementary business that helps diversify earnings.

Summary & Key Takeaways

• Merck beat Q2 earnings expectations, but revenue declined by 11% YoY and the company lowered its revenue guidance by 2%.

• The company's HPV vaccine, Gardasil, had impressive growth of 18% and is on track to be a blockbuster product. Its diabetes franchise also experienced growth.

• Emerging markets, especially China, are an important growth driver for Merck, but concerns arise from potential government intervention and lowered drug pricing.

• Sales of Merck's top-selling drug, Singulair, suffered due to patent expiration, and consumer health division was down due to cancellation of distribution agreements in China.